⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMEA News
Biomea Fusion, Inc. Common Stock
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
globenewswire.com
BMEA
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion to Participate at Upcoming Investor Conferences
globenewswire.com
BMEA
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
globenewswire.com
BMEA
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
BMEA
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
globenewswire.com
BMEA
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
globenewswire.com
BMEA